Business
MedMira Embarks on Major U.S. Expansion with VWR International, LLC Agreement
Deal Dramatically Increases U.S. Access to Patented Rapid Testing Technology HALIF...
About this update from Medmira Inc.
[{"type":"text","content":"\n\n\nDeal Dramatically Increases U.S. Access to Patented Rapid Testing\n Technology\n\n\nHALIFAX, Jan. 13, 2014 /CNW/ - MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid testing technologies and solutions, today\n announced a U.S. distribution agreement with VWR International LLC, a\n global solutions provider of laboratory supplies and services with\n worldwide sales in excess of $4.1 billion in 2012.\n\n\nThrough this new agreement, MedMira will benefit from the breadth and\n depth of VWR's experience in reaching various U.S. industries including\n research, education and healthcare.  VWR is selling MedMira's Miriad\n platform technology as well as its Reveal G3 rapid HIV test.  In the\n future, MedMira and VWR will expand more rapid testing products to its\n portfolio.\n\n\n\"MedMira's proven technology and rapid tests will offer our customers\n the benefits of faster test times and simplified test procedures,\" said\n Mark McLoughlin, Senior Vice President and President of VWR's U.S. Lab\n Business. \"We are very excited to add MedMira's products to our\n extensive portfolio and to work closely with MedMira on their strategic\n U.S. expansion.\"\n\n\n\"This agreement is a cornerstone of the foundation for MedMira's future\n strategy,\" said Kevin Jones, Ph.D., senior director, global sales and\n marketing, MedMira. \"VWR has more than 300 U.S. representatives on the\n ground every day, in laboratories, universities and businesses in a\n variety of industries. We are thrilled and committed to work alongside\n VWR to bring our technologies and solutions to a much broader U.S. user\n base than we previously were able to reach.\"\n\n\nThe U.S. accounts for 40 percent of global in vitro diagnostics sales,\n which are expected to reach an estimated value of $74.2 billion\n globally by 2018 (Transparency Market Research). Rapid testing for\n diseases such as HIV and Hepatitis are an increasingly important\n segment of the U.S. diagnostics industry.  The CDC recently implemented\n revised guidelines calling for routine HIV screening of all people aged\n 15-65 and all pregnant women in the U.S. as part of the normal course\n of medical care.  Public health organizations in the U.S. are also\n ramping up screening programs to detect Hepatitis C infection; it is\n estimated that there are 3.2 million people...